Mexican Regulators Approve Zydus’ Herceptin Biosimilar

The Company Has Secured A Second Biosimilar Approval In Mexico With Trastuzumab

 
• By Adam Zamecnik

Doubling down on its Latin American strategy, Zydus has managed to snap up a second biosimilar approval in Mexico, paving the way for future launches.

Mexican flag on map of Mexico
Zydus has snagged a second biosimilar approval in Mexico • Source: Shutterstock

Mexico’s health agency COFEPRIS has approved Zydus Lifesciences’ Herceptin (trastuzumab) biosimilar, doubling down on the Indian pharma’s efforts in the North American nation after a recent approval of the firm’s bevacizumab biosimilar.

Marketed under the name Mamitra, the trastuzumab biosimilar will be available in two strengths of 150mg and 440mg as a treatment for patients with HER2 overexpressing metastatic breast cancer,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.